Personalized chemo dosing aims to beat tough testicular cancers
NCT ID NCT00864318
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a high-dose chemotherapy regimen called TICE in 101 patients with germ cell tumors that had relapsed or were not responding to standard treatment. The approach uses two cycles of paclitaxel and ifosfamide followed by three cycles of carboplatin and etoposide, with carboplatin doses adjusted for each patient to reduce side effects. The goal was to improve complete response rates while controlling toxicity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel, ifosfamide, carboplatin, and etoposide (chemotherapy drugs)
What this could lead to
If successful, this could offer a more effective treatment option for patients with hard-to-treat germ cell tumors, potentially improving survival rates.
What could go wrong
This is a phase 2 trial with a small number of participants, so results may not apply to everyone. High-dose chemotherapy carries serious risks like ear toxicity and kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU
Clermont-Ferrand, 63003, France
-
CHU
Strasbourg, 67091, France
-
Centre Antoine Lacassagne
Nice, 06050, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Centre Paul Papin
Angers, 49933, France
-
Hopital St André
Bordeaux, 33075, France
-
Hopital TENON
Paris, 75970, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31052, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli Calmette
Marseille, 13273, France
-
Institut Val d'aurelle
Montpellier, 34298, France